Misuse of Drugs Act
Part III Class C Drugs
Source: L. A. King, Forensic Chemistry of Substance Misuse: A Guide to Drug Control, RSC Publishing, Cambridge, 2009
3D rendering of Trilostane
[Trilostane (above) is explicitly not captured by this clause]

Hydroxyandrostan-3-one skeleton
17-Hydroxyandrostan-3-one

Hydroxyestran-3-one
17-Hydroxyestran-3-one
Effective 1 Sep 1996, S.I. 1996/1300 added:
1(c)
Any compound (not being Trilostane or a compound for the time being specified in sub-paragraph (b) above) structurally derived from 17-Hydroxyandrostan-3-one or from 17-Hydroxyestran-3-one by modification in any of the following ways, that is to say:
  1. by further substitution at position 17 by a methyl or ethyl group;
  2. by substitution to any extent at one or more of the positions 1, 2, 4, 6, 7, 9, 11 or 16, but at no other position;
  3. by unsaturation in the carbocyclic ring system to any extent, provided that there are no more than two ethylenic bonds in any one carbocyclic ring;
  4. by fusion of ring A with a heterocyclic system.
11 March 2016 · Creative Commons BY-NC-SA ·